Russia may start exports of domestic-developed COVID-19 drugs to Latin America and Asian regions

30 June 2020

Russia may start exports of Avifavir (favipiravir), which is a newly developed domestic drug, that could be recommended for the treatment of COVID-19, according to recent statements by Sergey Tsyb, deputy head of the Russian Ministry of Industry and Trade, reports The Pharma Letter’s local correspondent.

According to the official, Avifavir could be competitive with similar drugs against COVID-19, which are currently designed by some global drugmakers.

Avifavir, which is produced by a joint venture of the Russian Direct Investments Fund (RDIF) and the ChemRar group of companies, one of Russia’s leading drugmakers, is based on favipiravir – an antiviral medication, which has been used to treat influenza in Japan since 2014. It became the first of the two registered drugs against COVID-19 in Russia after the approval of Areplivir (another favipiravir-based drug) by the Russian Ministry of Health.

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK